ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

MD Anderson, Partner Launch Oncology Firm

by Rick Mullin
October 12, 2015 | APPEARED IN VOLUME 93, ISSUE 40

The University of Texas MD Anderson Cancer Center and Theraclone Sciences have launched a company called OncoResponse that will use Theraclone’s screening technology to identify therapeutic antibodies against novel targets from immuno-oncology-treated patients. MD Anderson will provide access to samples and data from patients who have responded well to cancer immunotherapies. OncoResponse has raised $9.5 million in financing from Arch Venture Partners, Canaan Partners, MD Anderson, and others.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment